Summary
BVF Chart
Why Bausch Health Stock Surged By Nearly 20%
Bausch Health surged by nearly 20% on high volume on Monday, rebounding from a post-earnings sell-off driven by high risk and debt concerns. Q2 results beat revenue and GAAP EPS estimates, with strong growth in Xifaxan and Solta Medical, but normalized EPS missed slightly. Debt reduction remains slow, with only $11 million paid down against $14.65 billion net debt.
Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript
Bausch Health Companies Inc. (NYSE:BHC ) Q2 2025 Earnings Conference Call July 30, 2025 5:00 PM ET Company Participants Garen Sarafian - VP & Head of Investor Relations Jean-Jacques Charhon - Executive VP & CFO Thomas J. Appio - CEO & Director Conference Call Participants Douglas Miehm - RBC Capital Markets, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Operator Welcome to the Bausch Health First Quarter 2025 Earnings Call.
Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bausch Health Companies Inc. Dividends
 BVF 10 Nov 2010 | Other | €1 Per Share |
| BVF 30 Aug 2010 | Other | €0.1 Per Share |
| BVF 31 May 2010 | Other | €0.1 Per Share |
Bausch Health Companies Inc. Earnings
| 29 Oct 2025 (In 1 month) Date | | 1.04 Cons. EPS | - EPS |
| 28 Oct 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 31 Jul 2025 Date | | 0.93 Cons. EPS | - EPS |
| 30 Jul 2025 Date | | 0.94 Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| BVF 10 Nov 2010 | Other | €1 Per Share |
| BVF 30 Aug 2010 | Other | €0.1 Per Share |
| BVF 31 May 2010 | Other | €0.1 Per Share |
| 29 Oct 2025 (In 1 month) Date | | 1.04 Cons. EPS | - EPS |
| 28 Oct 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 31 Jul 2025 Date | | 0.93 Cons. EPS | - EPS |
| 30 Jul 2025 Date | | 0.94 Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
Bausch Health Companies Inc. (BVF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Bausch Health Companies Inc. ever had a stock split?
Bausch Health Companies Inc. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Thomas J. Appio CEO | XMUN Exchange | CA0717341071 ISIN |
| CA Country | 20,700 Employees | 11 Jun 2014 Last Dividend | 16 Oct 2000 Last Split | - IPO Date |
Overview
Bausch Health Companies Inc. is a global player in the specialized pharmaceutical and medical device sector, with operations spanning both the United States and numerous other countries around the world. Its focus areas include gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. Originally known as Valeant Pharmaceuticals International, Inc., the company underwent a name change in July 2018, marking a new chapter in its history. Headquartered in Laval, Canada, the organization functions through five key segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb, each targeting specific market needs.
Products and Services
Bausch Health's diverse portfolio extends across various medical domains, including:
- Gastroenterology: Under the Salix segment, the company provides innovative products aimed at gastrointestinal health, catering primarily to the US market.
- International Pharmaceutical and Medical Devices: The International segment encompasses the distribution of branded and generic pharmaceuticals, OTC products, and aesthetic medical devices across different countries, focusing on meeting global health needs.
- Aesthetic Medical Devices: Through the Solta Medical segment, Bausch Health engages in the development and sale of cutting-edge aesthetic devices, showcasing its commitment to advancing beauty and dermatological care.
- Diversified Products: The Diversified segment offers a wide range of pharmaceuticals in neurology and various other therapeutic classes, including generic products, ortho dermatologic products, and dentistry products within the US. This diversification underscores the company's holistic approach to healthcare.
- Vision Care and Ophthalmic Products: The Bausch + Lomb segment, named after the well-known eye health brand, provides a comprehensive line of products to address vision care, surgical requirements, and ophthalmic pharmaceutical needs, underlining Bausch Health's prominence in eye health solutions.
Contact Information
